GE HealthCare Beats Q3, Raises 2026 Guidance; PCS Segment CEO to Depart
GEHC sits 27% above its 52-week low of $58.75.
Summary
GE HealthCare beat Q3 expectations with 7.2% revenue growth and $1.34 adjusted EPS, raised full-year guidance, and disclosed the departure of its Patient Care Solutions segment CEO.
Key Events · Earnings and Guidance · GEHC
-
Q3 Beat With Raised Guidance
Revenue of $5.5 billion rose 7.2% (6.2% organic) and Adjusted EPS of $1.34 grew 25.1%. Full-year 2026 Adjusted EPS guidance was raised to $4.95-$5.05 from $4.80-$5.00, and organic revenue growth to ~4.0% from 3.0%-4.0%.
-
Margin Expansion Across All Segments
Adjusted EBIT margin rose 180 bps to 16.6% on volume, price and cost productivity plus a favorable tariff swing. Patient Care Solutions led with segment EBIT margin up 480 bps to 8.6%.
-
PCS Segment CEO Departing
Jeannette Bankes will resign as President and CEO of Patient Care Solutions effective November 15, 2026 to take a CEO role at another public company. Neal Sandy, head of PCS Product Strategy and Management, succeeds her on November 16, 2026.
-
Dividend Raised 14%
The board declared a quarterly dividend of $0.04 per share, up 14% from the prior quarter, payable to stockholders of record as of October 23, 2026.
Analysis · GEHC · Industrial Applications And Services
GE HealthCare beat its own expectations for the third quarter and lifted full-year guidance across the board: Adjusted EPS to $4.95-$5.05 from $4.80-$5.00, organic revenue growth to ~4.0%, and free cash flow to $1.6B+. Margin expansion came from volume, price and cost productivity plus a favorable tariff swing, with Adjusted EBIT margin up 180 bps to 16.6%. Against that, the filing discloses that Jeannette Bankes, who runs the Patient Care Solutions segment, is leaving November 15 for a CEO role elsewhere; PCS just posted its strongest margin improvement (up 480 bps to 8.6%), so the handoff to Neal Sandy on November 16 is the operational item to track. The 14% dividend increase to $0.04 a quarter is a modest but deliberate capital-return step alongside the pending $945M SOFIE Biosciences acquisition.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GEHC was trading at $74.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $32.1B. The 52-week trading range was $58.75 to $89.77. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.